BioSpace News Archive

Paradigm Spine, LLC, a leader in providing solutions for the treatment of lumbar spinal stenosis announces issuance of a Highmark.

Blinded period evaluated the safety of Viaskin Peanut versus placebo in children four to 11 years of age, Including patients with a history of severe anaphylaxis.

METTLER TOLEDO is pleased to announce the publication of its new, limited-edition lab calendar for 2018.

With this transaction, Lesaffre will enhance its presence and product offering in the fast-growing nutritional ingredients and health sector.

The total net proceeds from the offering for AxoGen are estimated to be approximately $15.4 million

The company’s revenues for the third quarter of 2017 increased by 27% over the revenues in the second quarter of 2017.

The publication describes a study in which Adipose Derived Regenerative Cells, the active component of Cytori Cell Therapy, were injected into deep partial thickness wounds in a porcine model, considered the gold standard preclinical model of hypertrophic scarring.

All prescriptions of Sucraid (sacrosidase) Oral Solution will be filled and distributed exclusively by U.S. Bioservices.

The app update includes support for DarioHealth’s new Lightning compatible device for iPhone 7 and iPhone 8 which was recently awarded the CE Mark.

Daiichi Sankyo today announced the first patient has been enrolled in DESTINY-Gastric01, a pivotal phase II study in Japan and South Korea evaluating the safety and efficacy of DS-8201, an investigational HER2-targeting ADC, in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma resistant or refractory to trastuzumab.